(Q54475803)

English

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

multiple sclerosis

0 references

0 references

Martin Krakauer

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Finn Sellebjerg

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

author name string

L P Ryder

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

I Alsing

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

P E H Jensen

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

N Koch-Henriksen

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

A Svejgaard

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

P Soelberg Sørensen

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

22 June 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

European Journal of Neurology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1291-1298

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19558503%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

Drug Insight: interferon treatment in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Appearance and disappearance of neutralizing antibodies during interferon-beta therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Interferon-beta: the neutralizing antibody (NAb) titre predicts reversion to NAb negativity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Evaluation of bioavailability of three types of IFNbeta in multiple sclerosis patients by a new quantitative-competitive-PCR method for MxA quantification.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Gene expression analysis of interferon-beta treatment in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

IFN-beta1b induces transient and variable gene expression in relapsing-remitting multiple sclerosis patients independent of neutralizing antibodies or changes in IFN receptor RNA expression.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Biological responsiveness to first injections of interferon-beta in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

G1P3, an IFN-induced survival factor, antagonizes TRAIL-induced apoptosis in human myeloma cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Interferon-beta induces transient systemic IP-10/CXCL10 chemokine release in patients with multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2009.02716.X

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q54475803&oldid=1107796074"